Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma (POLARIS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Eurofarma Laboratorios S.A..
Recruitment status was  Recruiting
Sponsor:
Collaborators:
CIM
CENCEC
Information provided by (Responsible Party):
Eurofarma Laboratorios S.A.
ClinicalTrials.gov Identifier:
NCT01145170
First received: June 14, 2010
Last updated: January 31, 2012
Last verified: January 2012

June 14, 2010
January 31, 2012
December 2010
September 2012   (final data collection date for primary outcome measure)
Tumor Volume [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

A Magnetic Resonance Imaging (MRI) will be used for measuring the tumor volume and it will be performed before the enrollment in the clinical study and every 12 weeks. The patient follow-up will be performed for 2 years after his/her inclusion in the investigation. The final evaluation will be performed 2 years after the inclusion of the last patient.

The main response variable will be the progression-free survival by 6 months.

efficacy [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

A Magnetic Resonance Imaging (MRI) will be used for measuring the tumor volume and it will be performed before the enrollment in the clinical study and every 12 weeks. The patient follow-up will be performed for 2 years after his/her inclusion in the investigation. The final evaluation will be performed 2 years after the inclusion of the last patient.

The main response variable will be the progression-free survival by 6 months.

Complete list of historical versions of study NCT01145170 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma
Use of Nimotuzumab and Radiotherapy in the Treatment of Pediatric Patients With Diffuse Intrinsic Brainstem Glioma

The study consists in only one treatment group, which will receive the first-line therapy for the disease - standard radiotherapy and a 150 mg/m2 dose of the investigational product (nimotuzumab)

General Purpose

1. To determine the therapeutic efficacy of the treatment with nimotuzumab in combination with radiotherapy in pediatric patients with diffuse intrinsic astrocytic of the brainstem glioma

Specific Purposes

  1. To determine the efficacy regarding the event-free survival (EFS) rate by 6 months of treatment.
  2. To determine the overall survival time of the patients with diffuse intrinsic astrocytic tumors of the cerebral trunk treated with combined radiotherapy and nimotuzumab.
  3. To determine the antitumoral objective response of the patients treated with combined radiotherapy and nimotuzumab.
  4. To determine the duration time of the response in the cases of objective response reached (CR or PR) or disease stabilization.
  5. To assess the toxicity of the combination AcM h-R3-nimotuzumab and radiotherapy in the patients enrolled in the clinical study.
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Diffuse Intrinsic Brainstem Gliomas
  • Radiation: Radiotherapy
    Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
  • Biological: Nimotuzumab
    The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
Experimental: Nimotuzumab
The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
Interventions:
  • Radiation: Radiotherapy
  • Biological: Nimotuzumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
December 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Pediatric patients with diffuse intrinsic brainstem gliomas, documented by standard imaging techniques (MRI). Note: Tumor biopsy and histological confirmation are not required in this study.
  2. Patients eligible for radiotherapy with Cobalt60. The patients should not have received a previous specific oncological treatment.
  3. Aged > 3 years old < 18 years old
  4. Patients with measurable lesions, defined as those that can be accurately measured in at least 2 dimensions (the 2 largest perpendicular diameters), using standard techniques (MRI).
  5. Female patients with childbearing potential should present a negative pregnancy test and adopt effective birth control methods, in case they are sexually active.
  6. Male patients who can father a child should adopt effective birth control methods, in case they are sexually active.
  7. Life expectancy > 12 weeks
  8. Health general status, according to Karnofsky Index > 40% (Karnofsky Index for patients > 16 years old), Lansky > 40% (for patients < 16 years old)
  9. Laboratory parameters within the normal limits, defined as: Hematopoietic: Hemoglobin > 10 g/L, Total Leukocytes > 2 x 109 cells/L, Platelets > 100 x 109/L; Hepatic: Liver functioning within the normal limits and without hepatic diseases demonstrated by ALT, AST < 2.5 x above the reference value and Total Bilirubin < 1.5 x above the reference value; Renal function: Serum Creatinine < 1.5 x above the reference value.
  10. The parents or legal guardians should express, voluntarily, in writing, that the patient will be enrolled in the study upon signature of the informed consent form. At the investigator's discretion, where applicable, the consent will be obtained from the minor.

Exclusion Criteria:

  1. Low-grade brainstem glioma (e.g., focal, cervicomedullary, tectal brainstem glioma).
  2. Patients previously treated with some AcM.
  3. Patients previously treated with some antineoplastic therapy, including chemotherapy, immunotherapy or radiotherapy.
  4. Concurrent treatment with some antineoplastic therapy not conceived in the study protocol.
  5. Breastfeeding or pregnant patients.
  6. Patients that, at the time of enrollment, have some related chronic disease under decompensation (e.g., cardiopathy, diabetes, hypertension).
  7. Patients who have history of hypersensitivity to this or another similar product.
  8. Fever, severe septic processes and/or severe or acute allergy.
  9. Patients who are participating in another clinical study with therapeutic purposes for their disease based on the time of the study enrollment.
  10. Presence of a second tumor.
Both
3 Years to 18 Years
No
Brazil,   Cuba
 
NCT01145170
EF090
Yes
Eurofarma Laboratorios S.A.
Eurofarma Laboratorios S.A.
  • CIM
  • CENCEC
Principal Investigator: Sidnei Epelman Casa de Saúde Santa Marcelina
Principal Investigator: Vicente Odone Filho Hospital das Clínicas da Faculda de Medicina da USP
Principal Investigator: Algemir L Brunetto Hospital de Clínicas de Porto Alegre
Principal Investigator: Claudia T Oliveira Hospital Amaral Carvalho
Eurofarma Laboratorios S.A.
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP